Vivo Bio Tech
BSE: VIVOBIOT · Biotechnology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vivo Bio Tech's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vivo Bio Tech Limited provides comprehensive preclinical research and development services to the pharmaceutical and biotechnology sectors. The company specialises in toxicology, pharmacology, and pharmacokinetic assessments, alongside the breeding and distribution of laboratory animals for biomedical research.
Business Model
The company generates revenue through contract research services and the supply of high-quality laboratory animal models to academic institutions and multinational pharmaceutical firms. It leverages its GLP-compliant facility in Telangana to provide specialised testing and drug discovery support.
Growth Outlook
Growth is driven by the increasing demand for outsourced preclinical research services and the expansion of drug discovery pipelines globally. The company aims to capitalise on its specialised infrastructure to support complex biomedical research requirements.
Key Risks
- Regulatory Compliance. Failure to maintain Good Laboratory Practice (GLP) standards could lead to the loss of accreditations and suspension of research operations.
- Ethical and Animal Welfare Regulations. Stricter government regulations regarding the use of laboratory animals in research could increase operational costs or limit business activities.
- Client Concentration. Reliance on a limited number of large pharmaceutical corporations for significant contract revenue poses a risk to financial stability.
- Technological Obsolescence. Rapid advancements in alternative testing methods, such as in-silico modelling or organ-on-a-chip technology, may reduce demand for traditional animal-based research.
Start your research today
Unlock AI insights, financials, peers and live data on Vivo Bio Tech and 5,000+ companies — free.
Key Metrics
REVENUE
₹53 Cr
TTM · consolidated
NET PROFIT
₹9 Cr
TTM · consolidated
EPS
₹4.27
TTM · consolidated
RETURN ON EQUITY
10.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
8.6%
TTM · consolidated
P/E
5.5x
Q4 FY26 · consolidated
EV/EBITDA
5.6x
Q4 FY26 · consolidated
EBITDA MARGIN
41.0%
TTM · consolidated
NET PROFIT MARGIN
36.3%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.7x
Q4 FY26 · consolidated
Peers · Biotechnology
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Vivo Bio TechVIVOBIOT | ₹40 Cr | 4.24 | 4.85 | 14.3% | 41.0% | 10.5% | 8.6% | -50.8% |
Anthem Biosciences Ltd.ANTHEM | ₹50,693 Cr | 131.02 | 53.09 | — | 47.5% | 18.9% | 25.4% | +10.0% |
Advanced Enzyme Technologies LimitedADVENZYMES | ₹3,357 Cr | 20.23 | 12.45 | 12.2% | 35.0% | 11.3% | 14.3% | -13.3% |
As of Q4 FY26
Financials
Vivo Bio Tech
BSE: VIVOBIOT · Biotechnology
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vivo Bio Tech's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vivo Bio Tech Limited provides comprehensive preclinical research and development services to the pharmaceutical and biotechnology sectors. The company specialises in toxicology, pharmacology, and pharmacokinetic assessments, alongside the breeding and distribution of laboratory animals for biomedical research.
Business Model
The company generates revenue through contract research services and the supply of high-quality laboratory animal models to academic institutions and multinational pharmaceutical firms. It leverages its GLP-compliant facility in Telangana to provide specialised testing and drug discovery support.
Growth Outlook
Growth is driven by the increasing demand for outsourced preclinical research services and the expansion of drug discovery pipelines globally. The company aims to capitalise on its specialised infrastructure to support complex biomedical research requirements.
Key Risks
- Regulatory Compliance. Failure to maintain Good Laboratory Practice (GLP) standards could lead to the loss of accreditations and suspension of research operations.
- Ethical and Animal Welfare Regulations. Stricter government regulations regarding the use of laboratory animals in research could increase operational costs or limit business activities.
- Client Concentration. Reliance on a limited number of large pharmaceutical corporations for significant contract revenue poses a risk to financial stability.
- Technological Obsolescence. Rapid advancements in alternative testing methods, such as in-silico modelling or organ-on-a-chip technology, may reduce demand for traditional animal-based research.
Start your research today
Unlock AI insights, financials, peers and live data on Vivo Bio Tech and 5,000+ companies — free.
Key Metrics
REVENUE
₹53 Cr
TTM · consolidated
NET PROFIT
₹9 Cr
TTM · consolidated
EPS
₹4.27
TTM · consolidated
RETURN ON EQUITY
10.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
8.6%
TTM · consolidated
P/E
5.5x
Q4 FY26 · consolidated
EV/EBITDA
5.6x
Q4 FY26 · consolidated
EBITDA MARGIN
41.0%
TTM · consolidated
NET PROFIT MARGIN
36.3%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.7x
Q4 FY26 · consolidated
Peers · Biotechnology
As of Q4 FY26